Giacomo Ruotolo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/118449/publications.pdf

Version: 2024-02-01

47 papers	3,740 citations	172386 29 h-index	214721 47 g-index
49 all docs	49 docs citations	49 times ranked	5225 citing authors

#	Article	IF	Citations
1	The dual glucoseâ€dependent insulinotropic polypeptide and glucagonâ€like peptideâ€1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p<scp>ost hoc</scp> analysis. Diabetes, Obesity and Metabolism, 2022, 24, 148-153.	2.2	48
2	Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 363-378.	1.8	49
3	The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes Care, 2020, 43, e22-e24.	4.3	9
4	Impact of Baseline Glycemic Control on Residual Cardiovascular RiskÂin Patients With Diabetes Mellitus and Highâ€Risk Vascular Disease Treated With Statin Therapy. Journal of the American Heart Association, 2020, 9, e014328.	1.6	11
5	The dual glucoseâ€dependent insulinotropic peptide and glucagonâ€like peptideâ€1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2451-2459.	2.2	83
6	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease. JAMA Cardiology, 2020, 5, 1136.	3.0	59
7	Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial. Diabetes and Vascular Disease Research, 2019, 16, 171-177.	0.9	9
8	Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With Highâ€Risk Vascular Disease: Insights From the ACCELERATE Trial. Journal of the American Heart Association, 2019, 8, e013790.	1.6	3
9	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Annals of the Rheumatic Diseases, 2018, 77, 988-995.	0.5	41
10	ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease. JAMA Cardiology, 2018, 3, 401.	3.0	42
11	A novel approach to measuring macrophage-specific reverse cholesterol transport in vivo in humans. Journal of Lipid Research, 2017, 58, 752-762.	2.0	22
12	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis, 2017, 261, 12-18.	0.4	32
13	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. New England Journal of Medicine, 2017, 376, 1933-1942.	13.9	593
14	Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 943-952.	2.9	42
15	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. Journal of the American College of Cardiology, 2015, 66, 2201-2210.	1.2	105
16	Potent peroxisome proliferator-activated receptor-Â agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. European Heart Journal, 2015, 36, 3020-3022.	1.0	29
17	Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. American Heart Journal, 2015, 170, 1061-1069.	1.2	74
18	Efficacy, Safety, Tolerability, and Pharmacokinetic Profile of Evacetrapib Administered as Monotherapy or in Combination With Atorvastatin in Japanese Patients With Dyslipidemia. American Journal of Cardiology, 2014, 113, 2021-2029.	0.7	27

#	Article	IF	Citations
19	Molecular study of human herpesvirus 6 and 8 involvement in coronary atherosclerosis and coronary instability. Journal of Medical Virology, 2012, 84, 1961-1966.	2.5	7
20	Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetologica, 2012, 49, 421-428.	1.2	89
21	Lack of association of apoE Îµ4 allele with insulin resistance. Acta Diabetologica, 2012, 49, 25-32.	1.2	18
22	Fatty liver index and mortality: The cremona study in the 15th year of follow-up. Hepatology, 2011, 54, 145-152.	3.6	208
23	Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian Individuals. Diabetes Care, 2011, 34, 210-215.	4.3	335
24	Diagnostic sensitivity of thyroid autoantibodies assessed in a population-based, cross-sectional study in adults. Autoimmunity Highlights, 2010, 1, 83-86.	3.9	3
25	Association Between Plasma Monocyte Chemoattractant Protein-1 Concentration and Cardiovascular Disease Mortality in Middle-Aged Diabetic and Nondiabetic Individuals. Diabetes Care, 2009, 32, 2105-2110.	4.3	80
26	The impact of dyslipidaemia on cardiovascular mortality in individuals without a prior history of diabetes in the DECODE Study. Atherosclerosis, 2009, 206, 298-302.	0.4	28
27	Preprocedure hyperglycemia is more strongly associated with restenosis in diabetic patients after percutaneous coronary intervention than is hemoglobin A1C. Cardiovascular Revascularization Medicine, 2007, 8, 15-20.	0.3	31
28	Lipoprotein(a), fibrinogen and vascular mortality in an elderly northern Italian population. Haematologica, 2006, 91, 1613-20.	1.7	10
29	A genetic and epidemiologic study of cardiovascular disease in Alaska natives (GOCADAN): design and methods. International Journal of Circumpolar Health, 2005, 64, 206-221.	0.5	52
30	Dietary Intakes Vary with Age among Eskimo Adults of Northwest Alaska in the GOCADAN Study, 2000â€“2003. Journal of Nutrition, 2005, 135, 856-862.	1.3	83
31	The Molecular Basis of Lecithin:Cholesterol Acyltransferase Deficiency Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1972-1978.	1.1	158
32	Fasting Plasma Leptin, Tumor Necrosis Factor-Â Receptor 2, and Monocyte Chemoattracting Protein 1 Concentration in a Population of Glucose-Tolerant and Glucose-Intolerant Women: Impact on cardiovascular mortality. Diabetes Care, 2003, 26, 2883-2889.	4.3	117
33	Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease in Nondiabetic American Indians: The Strong Heart Study. Diabetes Care, 2003, 26, 861-867.	4.3	376
34	Understanding the physiological and functional consequences of menopause: The PROSALMEN study. Aging Clinical and Experimental Research, 2002, 14, 170-177.	1.4	0
35	Dyslipidemia of the metabolic syndrome. Current Cardiology Reports, 2002, 4, 494-500.	1.3	132
36	Human Evidence That the Apolipoprotein A-II Gene Is Implicated in Visceral Fat Accumulation and Metabolism of Triglyceride-Rich Lipoproteins. Circulation, 2001, 104, 1223-1228.	1.6	96

#	Article	IF	Citations
37	Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. Journal of the American College of Cardiology, 2000, 35, 647-654.	1.2	81
38	Alimentary Lipemia, Postprandial Triglyceride-Rich Lipoproteins, and Common Carotid Intima-Media Thickness in Healthy, Middle-Aged Men. Circulation, 1999, 100, 723-728.	1.6	229
39	Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Journal of the American College of Cardiology, 1998, 32, 1648-1656.	1.2	155
40	Effects of a cardioselective Î²-blocker on postprandial triglyceride-rich lipoproteins, low density lipoprotein particle size and glucose-insulin homeostasis in middle-aged men with modestly increased cardiovascular risk. Atherosclerosis, 1998, 137, 391-400.	0.4	26
41	Influence of breast- and formula-feeding on plasma cholesterol precursor sterols throughout the first year of life. Journal of Pediatrics, 1997, 131, 928-931.	0.9	10
42	Lipoprotein profile after combined kidney-pancreas transplantation in insulin-dependent diabetes mellitus. Transplant International, 1995, 8, 190-195.	0.8	8
43	Evidence that apolipoprotein(a) phenoptype is a risk factor for coronary artery disease in men < 55 years of age. American Journal of Cardiology, 1994, 74, 346-351.	0.7	30
44	Acute presentation of Tangier polyneuropathy: a clinical and morphological study. Acta Neuropathologica, 1993, 86, 90-94.	3.9	16
45	Increased receptor binding of low-density lipoprotein from individuals consuming a high-carbohydrate, low-saturated-fat diet. Metabolism: Clinical and Experimental, 1992, 41, 1154-1160.	1.5	10
46	Apolipoprotein (a) levels in type 1 and type 2 diabetes mellitus. Acta Diabetologica, 1991, 28, 158-161.	1.2	12
47	Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes. Metabolism: Clinical and Experimental, 1990, 39, 598-604.	1.5	55